A Prospective Randomized Controlled Multicenter Study of the Effect of Dalteparin on Quality of Life in Unresectable Pancreatic Cancer.

Trial Profile

A Prospective Randomized Controlled Multicenter Study of the Effect of Dalteparin on Quality of Life in Unresectable Pancreatic Cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2015

At a glance

  • Drugs Dalteparin sodium (Primary) ; Gemcitabine (Primary)
  • Indications Pancreatic cancer; Thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Mar 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Feb 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Feb 2013 Planned end date (Sep 2014) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top